-

Dante Labs achieves ISO 13485 certification for its Genomic Interpretation Software Immensa, leveraging an 18 month long clinical validation study of 500,000 samples

original Dante Labs Automatic Lab (Photo: Business Wire)

Dante Labs Automatic Lab (Photo: Business Wire)

CAMBRIDGE, England--(BUSINESS WIRE)--Dante Labs, a world leader in genomic sequencing and data analysis, announced today that it received ISO 13485:2016 certification for its Immensa Genomic Interpretation Software as a medical device. The highly coveted industry certification involved a deep clinical validation study carried out by several teams at Dante Labs over an 18 month period. The accreditation was awarded by The British Standards Institution (BSI) Group.

“This is a great achievement for all of the team members at Dante Labs who worked very hard to implement a brand-new ISO-compliant quality system and develop the software,” says Dante Labs CEO Andrea Riposati. “The bioinformatics team ran a clinical validation study the size of a population genomics program.”

The most recent validation was completed in March 2021. It involved 500,000 samples, and used whole genome sequencing data sequenced using Illumina technology.

Dante Labs has already received the CE-IVD mark for its Immensa Software in 2020.

About Dante Labs

Dante Labs is a global genomic platform that integrates genomic and clinical data to provide better solutions in both diagnostics and therapeutics. Dante Labs’ genomic applications have an impact in the lives of patients and doctors, from rare diseases and oncology, to infectious diseases. To learn more, please visit www.dantelabs.com and follow @DanteLabs.

Contacts

Giorgio Lodi
giorgio.lodi@dantelabs.com

Industry:

DANTE OMICS

Details
Headquarters: New York, USA
CEO: Andrea Riposati
Employees: 42
Organization: PRI
Release Summary
Dante Labs achieves ISO 13485, leveraging an 18 month long clinical validation study of 500,000 samples.
Release Versions
English
Hashtags
#genomics
#sequencing

Contacts

Giorgio Lodi
giorgio.lodi@dantelabs.com

More News From DANTE OMICS

Dante Genomics Expands into Dante Omics AI: Pioneering the Future of Precision Healthcare

NEW YORK--(BUSINESS WIRE)--Dante Genomics, a global leader in AI-driven genomic analysis, has expanded into Dante Omics AI to reflect its evolution into a multiomics platform. By integrating genomics, RNA, proteomics, and spatial transcriptomics under one advanced AI framework, Dante Omics AI offers a comprehensive view of human biology, accelerating breakthroughs for clinics, doctors, researchers and biopharma. The expansion into multiomics started in 2023, pushed by requests by users and cust...

Dante Genomics to Launch Generative AI Features in Dante Labs Whole Genome Platform

NEW YORK--(BUSINESS WIRE)--Dante Genomics, a global leader in genomics and personalized medicine, announced today that it will begin integrating Generative AI features into its first product, the Dante Labs Whole Genome platform. This milestone represents a significant step forward in the company’s mission to make genomic data more actionable and accessible for both researchers and individuals. "Generative AI cannot be a black box in genomics and diagnostics," said Andrea Riposati, CEO and co-f...

Dante Omics Awarded Prestigious ISO 9001 Certification for Italian Laboratory

NEW YORK--(BUSINESS WIRE)--Dante Omics, a trailblazer in genomics-driven artificial intelligence solutions, is proud to announce that its cutting-edge laboratory in Italy has been awarded the internationally recognized ISO 9001:2015 certification for “Provision of genomic Next Generation Sequencing, analysis and interpretation services.” The ISO9001 certification was issued to Dante Labs Srl. This achievement marks a significant step in the company’s commitment to maintaining the highest standa...
Back to Newsroom